Equities

Angle PLC

AGL:LSE

Angle PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)14.50
  • Today's Change0.50 / 3.57%
  • Shares traded1.31m
  • 1 Year change-45.28%
  • Beta0.9084
Data delayed at least 20 minutes, as of Apr 26 2024 17:06 BST.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year Angle PLC's net income fell 44.46% from a loss of 15.01m to a larger loss of 21.69m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 1,017.77% to 1,401.44%.
Gross margin60.23%
Net profit margin-1,225.41%
Operating margin-1,346.26%
Return on assets-54.36%
Return on equity-69.68%
Return on investment-60.65%
More ▼

Cash flow in GBPView more

In 2022, Angle PLC did not generate a significant amount of cash. Cash Flow from Financing totalled 18.10m or 1,738.33% of revenues. In addition the company used 16.05m for operations while cash used for investing totalled 1.75m.
Cash flow per share-0.0784
Price/Cash flow per share--
Book value per share0.1231
Tangible book value per share0.1125
More ▼

Balance sheet in GBPView more

Angle PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.84% of the market capitalization can be attributed to its 31.90m and debt could be paid in full if management chose.
Current ratio7.51
Quick ratio6.93
Total debt/total equity0.1426
Total debt/total capital0.1248
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.